News Releases

This information is part of the archives and is no longer current and may no longer be accurate.

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
Dec 27, 2010REMOXY(R) New Drug Application ResubmittedPrinter Friendly Version
Nov 22, 2010DURECT to Present at the Piper Jaffray 2010 Health Care ConferencePrinter Friendly Version
Nov 08, 2010DURECT to Present at the Credit Suisse 2010 Healthcare ConferencePrinter Friendly Version
Nov 03, 2010DURECT Corporation Announces Third Quarter 2010 Financial ResultsPrinter Friendly Version
Nov 02, 2010DURECT Awarded $733,438 in Grants Under the Patient Protection and Affordable Care ProgramPrinter Friendly Version
Oct 27, 2010DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference CallPrinter Friendly Version
Sep 07, 2010DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 04, 2010DURECT Corporation Announces Second Quarter 2010 Financial ResultsPrinter Friendly Version
Jul 29, 2010DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference CallPrinter Friendly Version
Jul 28, 2010DURECT to Present at the BMO Capital Markets Focus on Healthcare ConferencePrinter Friendly Version
Jul 01, 2010DURECT Corporation Secures $50 Million Committed Equity Financing FacilityPrinter Friendly Version
Jun 16, 2010DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)Printer Friendly Version
Jun 07, 2010DURECT Corporation Invites You to Join a Conference Call Today Regarding its POSIDUR(TM) Collaboration with HospiraPrinter Friendly Version
Jun 07, 2010Hospira and DURECT Sign Agreement to Develop and Commercialize POSIDUR™(SABER™-Bupivacaine) in the U.S. and CanadaPrinter Friendly Version
Jun 01, 2010DURECT to Present at the Jefferies Global Life Sciences ConferencePrinter Friendly Version
May 13, 2010DURECT to Present at the Rodman & Renshaw Global Healthcare ConferencePrinter Friendly Version
May 10, 2010DURECT Corporation Announces First Quarter 2010 Financial ResultsPrinter Friendly Version
May 04, 2010DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference CallPrinter Friendly Version
Apr 07, 2010DURECT Corporation Announces Commencement of Phase IIb ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) Clinical Trial by King PharmaceuticalsPrinter Friendly Version
Mar 17, 2010DURECT to Present at the Barclays Capital Global Healthcare ConferencePrinter Friendly Version
Mar 01, 2010DURECT to Present at the Cowen and Company Healthcare ConferencePrinter Friendly Version
Feb 24, 2010DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial ResultsPrinter Friendly Version
Feb 22, 2010DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand TerritoryPrinter Friendly Version
Feb 17, 2010DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference CallPrinter Friendly Version
Jan 19, 2010DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical TrialPrinter Friendly Version